BRAF V600E and KRAS G12S mutations in peripheral nerve sheath tumours

Benign (BPNST) and malignant (MPNST) peripheral nerve sheath tumours occur either sporadically or are related to neurofibromatosis (NF). The mechanisms involved are well known in NF‐related tumours, but still remain unclear in sporadic cases. Somatic BRAF and KRAS mutations represent the most frequent genetic events in melanocytic neoplastic lesions. Because melanocytes and Schwann cells both derive from neural crest cells, we hypothesized that BRAF and KRAS mutations might influence BPNST and MPNST development.

[1]  Kirsten Schmieder,et al.  Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma , 2011, Acta Neuropathologica.

[2]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[3]  U. Suter,et al.  Schwann Cell Precursors from Nerve Innervation Are a Cellular Origin of Melanocytes in Skin , 2009, Cell.

[4]  T. de Ravel,et al.  Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1. , 2009, The Lancet. Oncology.

[5]  R. Lothe,et al.  Germline and somatic NF1 mutations in sporadic and NF1‐associated malignant peripheral nerve sheath tumours , 2009, The Journal of pathology.

[6]  D. Peeper,et al.  BRAFE600 in benign and malignant human tumours , 2008, Oncogene.

[7]  R. Ferner.  Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective , 2007, The Lancet Neurology.

[8]  D. Oliveira,et al.  Sporadic and multiple neurofibromas in the head and neck region: a retrospective study of 33 years , 2007, Clinical Oral Investigations.

[9]  M. Giovannini,et al.  Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac. , 2007, Cancer research.

[10]  O. Kranenburg,et al.  The KRAS oncogene: past, present, and future. , 2005, Biochimica et biophysica acta.

[11]  J. Shay,et al.  BRAFE600-associated senescence-like cell cycle arrest of human naevi , 2005, Nature.

[12]  L. Aaltonen,et al.  BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing , 2004, Journal of Medical Genetics.

[13]  D. Evans,et al.  Genotype-phenotype correlations for nervous system tumors in neurofibromatosis 2: a population-based study. , 2004, American journal of human genetics.

[14]  David J. Wilson,et al.  Absence of BRAF and NRAS mutations in uveal melanoma. , 2003, Cancer research.

[15]  D. Polsky,et al.  Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. , 2003, Cancer research.

[16]  J. Arbiser,et al.  Mitogen-actived protein kinase activation is an early event in melanoma progression. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  Richard Wooster,et al.  BRAF and RAS mutations in human lung cancer and melanoma. , 2002, Cancer research.

[18]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[19]  D. Evans,et al.  Malignant peripheral nerve sheath tumours in neurofibromatosis 1 , 2002, Journal of medical genetics.

[20]  D. Gutmann,et al.  NF1 deletions in S-100 protein-positive and negative cells of sporadic and neurofibromatosis 1 (NF1)-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors. , 2001, The American journal of pathology.

[21]  X. Matías-Guiu,et al.  K‐ras mutations in endometrial carcinomas with microsatellite instability , 2001, The Journal of pathology.

[22]  C. Fletcher,et al.  Expanding the Spectrum of Malignant Change in Schwannomas: Epithelioid Malignant Change, Epithelioid Malignant Peripheral Nerve Sheath Tumor, and Epithelioid Angiosarcoma: A Study of 17 Cases , 2001, The American journal of surgical pathology.

[23]  J. Woodruff,et al.  Schwannoma (Neurilemoma) with Malignant Transformation A Rare, Distinctive Peripheral Nerve Tumor , 1994, The American journal of surgical pathology.

[24]  S. Pulst,et al.  Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2 , 1993, Nature.

[25]  F. Collins,et al.  Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients , 1992, Nature.

[26]  D. Lowy,et al.  Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis , 1992, Cell.

[27]  K. Antman,et al.  Sarcomas of soft tissue and bone , 1991, Cancer.

[28]  P. Meltzer,et al.  High frequency of BRAF mutations in nevi , 2003, Nature Genetics.

[29]  F. Collins,et al.  Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis , 1993, Nature Genetics.

[30]  Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. , 1988, Archives of neurology.